Clinical Trials Browser

INDUSTRY × Breast Neoplasms × talazoparib × Clear all

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

Breast Neoplasms

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled 43 charts

Breast Neoplasms, Neoplasms

NCT05141708 2024-02-16

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

33 enrolled 9 charts

Breast Neoplasms

NCT04987931 2024-01-22

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

84 enrolled 11 charts

Breast Neoplasms

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Phase 1/2 Terminated

223 enrolled 50 charts

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01945775 2022-01-20

EMBRACA

Phase 3 Completed

431 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT03499353 2021-11-09

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2 Terminated

61 enrolled 63 charts

Breast Neoplasms

NCT02034916 2019-10-14

ABRAZO

Phase 2 Terminated

84 enrolled 21 charts

Breast Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma